Oscotec Inc (039200)

Currency in KRW
57,100
-2,200(-3.71%)
Delayed Data·
Earnings results expected in 7 days
039200 is included in our AI-picked strategies. See how they work
Fair Value
Day's Range
57,00058,900
52 wk Range
25,00066,000
Key Statistics
Bid/Ask
57,100.00 / 57,200.00
Prev. Close
59,300
Open
58,700
Day's Range
57,000-58,900
52 wk Range
25,000-66,000
Volume
34.01K
Average Volume (3m)
494.61K
1-Year Change
84.8631%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
039200 Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
75,000
Upside
+31.35%
Members' Sentiments
Bearish
Bullish
ProTips
Impressive gross profit margins

Oscotec Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Technical Indicators
Buy
Moving Averages
Buy

Oscotec Inc. operates as a biotechnology company, engages in the drug development, functional materials and related products, and dental bone graft material businesses. It develops SKI-O-703, a SYK inhibitor that is in Phase 2 clinical trials to treat rheumatoid arthritis and idiopathic thrombocytopenic purpura; SKI-G-801, a selective FLT3/AXL inhibitor, which is in Phase I clinical trial for the treatment of acute myeloid leukemia, as well as other solid tumors; and lazertinib, a 3rd generation EGFR inhibitor that is in Phase 3 clinical trials to treat non-small cell lung cancer, as well as Anti-Tau antibody, which is in Phase 1a/1b clinical trials for the treatment of Alzheimer’s disease. The company also offers dental health products, such as bone graft comprising InduCera, BioCera-F, and SynCeraII; and membrane consisting of LysoGide and CollaGuide. In addition, it provides functional ingredients comprises OPB for osteoporosis; AIF for arthritis; SGA that enhance bone growth; and PRF-K for perio diseases. The company was formerly known as Oscotec Co., Ltd and changed its name to Oscotec Inc. in June 1999. Oscotec Inc. was founded in 1998 and is headquartered in Seongnam-si, South Korea.

Employees
53

Compare 039200 to Peers and Sector

Metrics to compare
039200
Peers
Sector
Relationship
P/E Ratio
−172.7x−3.5x−0.5x
PEG Ratio
1.030.190.00
Price/Book
19.0x0.7x2.6x
Price / LTM Sales
97.6x0.8x3.1x
Upside (Analyst Target)
26.5%25.1%54.6%
Fair Value Upside
Unlock15.2%7.6%Unlock

Analyst Ratings

1 Buy
0 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 75,000
(+31.35% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate

Earnings

Latest Release
Nov 12, 2025
EPS / Forecast
-13.00 / --
Revenue / Forecast
8.95B / --
EPS Revisions
Last 90 days

039200 Income Statement

People Also Watch

19,610
214320
+0.36%
59,000
241560
+2.25%
47,350
281820
+2.71%
513,000
128940
+2.60%
16,140
005440
+3.46%

FAQ

What Is the Oscotec (039200) Stock Price Today?

The Oscotec stock price today is 57,100 KRW.

What Stock Exchange Does Oscotec Trade On?

Oscotec is listed and trades on the KOSDAQ.

What Is the Stock Symbol for Oscotec?

The stock symbol for Oscotec is "039200."

What Is the Oscotec Market Cap?

As of today, Oscotec market cap is 2.15T KRW.

What Is Oscotec's Earnings Per Share (TTM)?

The Oscotec EPS (TTM) is -344.

When Is the Next Oscotec Earnings Date?

Oscotec will release its next earnings report on Mar 24, 2026.

From a Technical Analysis Perspective, Is 039200 a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Oscotec Stock Split?

Oscotec has split 3 times.

How Many Employees Does Oscotec Have?

Oscotec has 53 employees.

What is the current trading status of Oscotec (039200)?

As of Mar 17, 2026, Oscotec (039200) is trading at a price of 57,100 KRW, with a previous close of 59,300 KRW. The stock has fluctuated within a day range of 57,000 KRW to 58,900 KRW, while its 52-week range spans from 25,000 KRW to 66,000 KRW.

What Is Oscotec (039200) Price Target According to Analysts?

The average 12-month price target for Oscotec is 75,000 KRW, with a high estimate of 75000 KRW and a low estimate of 75000 KRW. 1 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +31.35% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.